Monday, December 5, 2016

AstraZeneca in broad drug deal with Bicycle worth up to $1 bln

LONDON, Dec 1 (Reuters) - AstraZeneca has signed a

wide-ranging deal with private biotech firm Bicycle Therapeutics

to develop a novel class of small molecule medicines for

treating respiratory, cardiovascular and metabolic diseases.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)